Therapeutic Goods Administration Decides Not To Register Lecanemab In Australia
In October 2024, the TGA made the decision not to register lecanemab in Australia for the treatment of patients with early AD. In December 2024, Eisai requested reconsideration of the decision, ...
BioArctic: Therapeutic Goods Administration decides not to register lecanemab in Australia
BioArctic AB's (publ) (NASDAQ: BIOA B) (STOCKHOLM: BIOA B) partner Eisai announced today that the Therapeutic Goods Administration (TGA) of Australia ...
JCN Newswire6h
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease
Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ...
NJBIZ2d
More layoffs coming to NJ’s pharma sector
Along with Nutley-based Eisai, several other New Jersey-based giants in the space have conducted layoffs over the past few ...
BioSpace2d
Eisai Will Trim About 7% of US Workforce, Including New Jersey Employees
Eisai’s cuts will affect 121 employees across the Japanese company’s U.S. operations, including 57 people at its American ...
BioArctic: The Committee for Medicinal Products for Human Use (CHMP) reaffirms positive opinion for Lecanemab in early Alzheimer's disease in the EU
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced today that the Committee for Medicinal Products for Human Use (CHMP) ...